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ABSTRACT 
MacB is an ABC transporter that collaborates with the MacA adaptor protein and TolC exit duct to 
drive efflux of antibiotics and enterotoxin STII out of the bacterial cell. Here we present the structure 
of ATP-bound MacB and reveal precise molecular details of its mechanism. The MacB 
transmembrane domain lacks a central cavity through which substrates could be passed but instead 
conveys conformational changes from one side of the membrane to the other; a process we term 
mechanotransmission. Comparison of ATP-bound and nucleotide-free states reveals how reversible 
dimerization of the nucleotide binding domains drives opening and closing of the MacB periplasmic 
domains via concerted movements of the second transmembrane segment and major coupling helix. 
We propose the assembled tripartite pump acts as a molecular bellows to propel substrates through the 
TolC exit duct, driven by MacB mechanotransmission. Homologues of MacB that do not form 
tripartite pumps but share structural features underpinning mechanotransmission include the LolCDE 
lipoprotein trafficking complex and FtsEX cell division signaling protein. The MacB architecture 
serves as the blueprint for understanding the structure and mechanism of an entire ABC transporter 
superfamily and the many diverse functions it supports. 
 
SIGNIFICANCE 
Bacterial ABC transporters typically mediate transport of substrates across the cytoplasmic membrane 
using either alternating access or toppling based mechanisms. The non-canonical ABC transporter 
MacB does not behave in this manner, but instead couples cytoplasmic ATP hydrolysis with 
periplasmic conformational changes that drive substrates from the periplasm to the extracellular space 
via the TolC exit duct. Here we describe the ‘mechanotransmission’ mechanism of MacB in molecular 
detail by comparing ATP-bound and nucleotide-free structures. We further show that MacB shares its 
structural architecture with an entire superfamily of ABC transporters responsible for fundamental 
bacterial processes including cell division and outer membrane biogenesis suggesting a common mode 
of operation, and raise the possibility of targeting such proteins for development of new antibiotics. 
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Tripartite efflux pumps (TEPs) span the inner and outer membranes of Gram-negative bacteria to 
mediate export of protein toxins, antibiotics and virulence factors (1). In E. coli, the inner membrane 
ABC transporter MacB (2), adaptor protein MacA and the TolC exit duct (3) form a TEP that confers 
resistance to macrolide antibiotics (2, 4, 5) and exports heat stable enterotoxin STII (6, 7). ABC 
transporters are composed of nucleotide binding domains (NBDs) required for ATP hydrolysis, and 
transmembrane domains (TMDs) that typically facilitate passage of the substrate through the 
membrane in which they reside using an alternating access or toppling mechanism (8, 9). MacB is 
unlikely to use such mechanisms for enterotoxin transport as it resides in the inner membrane and 
transports enterotoxin STII from the periplasm to the extracellular space (6). 
 
MacB contains four transmembrane helices, an N-terminal NBD, and an extensive periplasmic domain 
located between TM1 and TM2 (10, 11). MacB homologues operate either within, or independently of, 
TEPs to perform a multitude of roles (12, 13). TEP-independent MacB homologues include key 
proteins involved in lipoprotein trafficking (LolCDE) and cell division (FtsEX) (12). LolCDE extracts 
lipoproteins from the inner membrane to a periplasmic chaperone (14) while FtsEX is thought to alter 
conformation of its periplasmic domain to recruit and activate periplasmic peptidoglycan hydrolases 
during bacterial cell division (15). Like MacB, LolCDE and FtsEX do not transport substrates across 
the inner membrane but instead use cytoplasmic ATP hydrolysis to perform work in the periplasm. 
 
Here, we present the crystal structure of ATP-bound MacB at 3.35 Å that in combination with a 
nucleotide-free form derived from a cryoEM structure of the MacAB-TolC assembly (11) reveals a 
mechanotransmission mechanism. We demonstrate that MacB is representative of a wider family of 
ABC transporters that use the same architecture and mechanism to perform diverse biological 
functions. 
 
 
RESULTS 
 
The crystal structure of MacB defines a new ABC transporter fold. We determined structures of 
ATP-bound MacB using X-ray crystallography. After screening multiple MacB homologues, crystals 
of Aggregatibacter actinomycetemcomitans (hereafter Aa) MacB were obtained in two space groups, 
P6522 and P21 and their structures solved at 3.90 Å and 3.35 Å resolution, respectively. Structures of 
the E. coli MacB periplasmic domain (1.95 Å) and cytoplasmic NBD (2.40 Å) were also determined. 
Structure determination for full-length AaMacB was achieved using a combination of molecular 
replacement with the individual domains and selenomethionine-based anomalous scattering 
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approaches. X-ray data and refinement statistics are given in Tables S1 & S2 and representative 
electron density for the full-length MacB structure is shown in Movie 1. 
 
The structure of AaMacB is shown in Fig. 1a coloured consistently with its linear domain arrangement 
(Fig. 1b) and transmembrane topology (Fig. 1c). Each MacB monomer within the dimer contains four 
transmembrane helices (TM1-4, blue), an N-terminal nucleotide-binding domain (NBD, red), and a 
198-residue periplasmic domain (purple) located between TM1 and TM2. The periplasmic domain is 
itself made up of two subdomains; the Sabre (Small alpha/beta rich extracytoplasmic) subdomain is 
composed of a single contiguous region of the MacB polypeptide (residues 347-465) and the Porter is 
formed from two β-α-β motifs (306-346 and 466-503) located either side of the Sabre-encoding region. 
The entire periplasmic domain is elevated above the cytoplasmic membrane by a 4-helix bundle (Fig. 
1a, stalk) comprising extensions of TM1 and TM2 from both monomers that interact along the dimer’s 
symmetry axis. TM3 and TM4 are both shorter than TM1 and TM2 and are not involved in 
dimerization, packing on the outside of the 4-helix bundle. An 8-residue loop connects TM3 and TM4 
on the periplasmic side straddling the interface between the outer leaflet of the cytoplasmic membrane 
and the periplasm (Fig. 1a, shoulder). On the cytoplasmic side of TM1, an 18-amino acid amphipathic 
helix (teal, 246-263) runs parallel with the plane of the membrane and is connected to the NBD by a 
41-residue ‘skirting loop’ (grey, residues 224-264) that lacks secondary structure and is highly flexible. 
Residues 242-246 are too disordered to model. A short helix located between TM2 and TM3 forms the 
major coupling helix (green, residues 548-556) and an additional interaction with the NBD is made by 
the C-terminus (minor coupling helix, orange, residues 637-646).  
 
The fold and topology of the MacB transmembrane and periplasmic domain are strikingly different to 
the six currently recognised ABC transporter superfamilies (SI Appendix, Fig. S1). The key 
distinguishing features of MacB are its four transmembrane helix topology, periplasmic domain, and 
stalk. MacB also has a rigid transmembrane dimerization interface dominated by hydrophobic 
interactions and lacks transmembrane cavities (SI Appendix, Fig. S2). The MacB structure supports 
previous bioinformatics-based analyses suggesting it belongs to a distinct monophyletic group with an 
independent evolutionary origin to all other ABC transporters that have been structurally characterised 
(12, 13). We therefore designate MacB as the ‘type specimen’ for a new ABC transporter superfamily 
on the basis of its novel topology, dimerization interface, and transmembrane fold - all of which are 
unique to MacB. 
 
Mode of ATP-binding in MacB. The structures presented here represent ATP-bound conformations 
of MacB in which the two cytoplasmic ATP binding sites are each occupied by a single nucleotide. 
The locations of the ATP-binding sites are shown in Fig. 1d and an omit map showing unbiased 
electron density for one of the nucleotides appears in Fig. 1e and Movie 2. The ATP binding mode is 
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similar to that seen in other ABC transporters (8, 9), with the nucleotides sandwiched between 
dimerized NBDs. The ATP phosphates are co-ordinated by a bound magnesium ion and Lys46 (Lys47 
in E. coli). The catalytic glutamate, Glu169 (Glu170 in E. coli, here mutated to glutamine), is 
positioned directly adjacent to the γ-phosphate consistent with a role in ATP hydrolysis. The MacB 
major coupling helix interacts intra-molecularly with a groove on the surface of the NBD providing a 
probable means by which conformational changes associated with the nucleotide binding and 
hydrolysis cycle are conveyed to the transmembrane domain. The MacB NBDs may operate as a 
conformational switch (16). 
 
MacB confers resistance to antibiotics and supports enterotoxin STII secretion. E. coli MacB was 
first identified and named for its role in macrolide resistance (2), but has since been shown to transport 
enterotoxin STII (6) and may have a role in protoporphyrin expulsion (17). To identify further MacB 
substrates, we determined the minimal inhibitory concentrations (MICs) of 11 distinct antimicrobial 
compounds against E. coli strains lacking chromosomal acrAB and macAB and expressing either 
plasmid-borne wild type or catalytically-inactive E. coli MacAB. The strain used lacks the broad-
spectrum RND efflux pump AcrAB facilitating detection of MacAB substrates that might otherwise be 
obscured. We observed a significant protective effect for MacAB against erythromycin, bacitracin and 
colistin (Fig. 2a, SI Appendix, Table S3). Identification of tolerance to bacitracin and colistin, both 
of which are cyclic peptides, shows MacB has a broader role in antibiotic resistance than previously 
recognised and is not limited to macrolides such as erythromycin. 
 
Having shown that MacB handles peptide-like antibiotics such as colistin and bacitracin, we further 
investigated its role in enterotoxin STII secretion. Enterotoxin STII is a 48-amino acid protein with 
two internal disulfide bonds that is produced as a virulence factor by enterotoxigenic E. coli (Fig. 2b). 
Expression of STII in E. coli leads to the appearance of mature toxin in the culture supernatant that is 
disrupted when chromosomal macAB genes are deleted. Secretion of STII is restored by 
complementation with wild type MacAB, but not by expression of either MacA or MacB alone, or by 
co-expression of MacAB with an ATPase-inactivating mutation (Glu170Gln) in MacB (Fig. 2c). Our 
experiments confirm a role for the MacAB-TolC efflux pump in secretion of enterotoxin STII (6, 18) 
and demonstrate MacB ATPase activity is required to extract this substrate from the periplasm and 
transport it to the extracellular space (Fig. 2d).  
 
Structure-led mutagenesis of macB identifies residues involved in antibiotic resistance. To probe 
the relationship between structure and function in MacB, we used site-directed mutagenesis to disrupt 
structural features within the NBD, transmembrane domain, stalk and periplasmic domain and tested 
each variant’s ability to confer resistance to erythromycin (SI Appendix, Table S4). The MIC results 
were colour-mapped to a homology model of E. coli MacB generated from the 
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A. actinomycetemcomitans full-length structure and E. coli soluble domains (Fig. 3). We first targeted 
residues on the cytoplasmic side of the membrane including residues shown to be mechanistically 
essential in MacB and other ABC systems (5, 9). As expected, mutation of residues involved in ATP 
binding (Lys47Ala) and hydrolysis (Glu170Gln) each reduced MIC values to levels comparable with 
that of the empty vector control (a 32-fold reduction) (Fig. 3a, d). Deletion of the minor coupling 
helix or disruption of an electrostatic interaction (Arg121-Glu256) between the amphipathic helix and 
NBD did not significantly affect MacB function showing these features are not essential (SI 
Appendix, Table S4). Next, we focussed on polar residues at the dimer interface. Alanine 
substitutions for Thr275, Ser285, Ser532, and Asn542 in the MacB transmembrane domain, and 
residues Thr517 and Thr520 in the periplasmic stalk, did not substantially affect MacB function 
suggesting these residues are unlikely to interact with substrates. Finally, through extensive 
mutagenesis of the periplasmic domain, we revealed an obvious ‘hotspot’ of residues on the interior 
surface indicating a plausible substrate interaction site (Fig. 3b, c, d). Key positions associated with 
the periplasmic hotspot are Tyr376, Phe444, Trp505 and Thr349, for which alanine substitution yields 
at least a 16-fold reduction in MIC, and Tyr315, Phe320, Phe503 and Met507 which each give 8-fold 
reductions. Further MIC determinations for a subset of MacB variants were performed using 
bacitracin and colistin revealing a similar pattern of MIC reduction to that of erythromycin suggesting 
the same periplasmic site is important for resistance to all of these molecules (SI Appendix, Fig. S3 & 
Table S5). 
 
We further tested our 70-strong cohort of MacB variants for their capacity to secrete enterotoxin STII. 
With the exception of Lys47Ala and Glu170Gln, all MacB variants were capable of toxin secretion 
(SI Appendix, Table S4). The reason for differential effects of periplasmic domain mutations on 
antibiotic resistance and enterotoxin secretion is not yet clear. One possibility is that the structure of 
enterotoxin presents multiple opportunities for productive interaction with MacB that render 
individual point mutations insufficient to disrupt transport. Alternatively, the site of enterotoxin 
interaction may be distinct from the site identified here relating to antibiotic resistance; a second site 
could plausibly be located, either in whole, or in part, elsewhere in MacB, or within another 
component of the tripartite assembly (MacA or TolC). We conclude that individual amino acids lining 
the interior face of the MacB periplasmic domain are vital for antibiotic resistance but dispensable for 
enterotoxin secretion, while residues associated with ATP binding and hydrolysis are essential for 
both. 
 
ATP-bound and nucleotide-free states of MacB reveal the molecular basis of 
mechanotransmission. We assessed the conformational changes associated with ATP-binding and 
hydrolysis by comparing our ATP-bound MacB with a nucleotide-free form extracted from a MacAB-
TolC assembly structure determined by cryoEM (11) (Fig. 4). After superposition of the two MacB 
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forms, we generated a molecular morph revealing the probable motions that link these states (Movie 
3). Our comparison reveals distinctive long-range conformational changes in the transmembrane and 
periplasmic domains linked to the nucleotide status of the NBD that we define here as 
‘mechanotransmission’. In the nucleotide-free form, the MacB NBDs are separated and a prominent 
V-shaped split is apparent in the periplasmic stalk (Fig. 4a left). The periplasmic head of MacB adopts 
an ‘open’ form with an obvious cavity between the two monomers (Fig. 4b). In the ATP-bound state, 
the cytoplasmic domains are dimerized and the two halves of the periplasmic stalk stand straight and 
perpendicular to the plane of the membrane (Fig. 4a right). In this form, the cavity within the 
periplasmic domain is absent and the entire structure is much more compact (Fig. 4c). Conformational 
changes apparent on both sides of the membrane are coordinated by the transmembrane domain, stalk 
and coupling helices. Specifically, upon ATP binding, NBD dimerization acts through the major 
coupling helix to push TM2 upwards through the membrane causing a shift in the register of opposing 
residues on either side of the dimer interface. The newly generated interface promotes association of 
the transmembrane domain and stalk into a rigid 4-helix bundle bringing together the periplasmic 
domains. Details of the dimer interface observed for each conformation are given in SI Appendix, Fig. 
S4. 
 
To validate the conformational changes observed by comparison of MacB structures, we used a 
disulfide cross-linking experiment testing whether restricting mechanotransmission impacts on activity. 
Guided by the structure, we produced a MacB cysteine variant (Thr517Cys) predicted to lock the stalk 
in its closed (‘zipped’) conformation and tested its ability to confer erythromycin tolerance (SI 
Appendix, Fig. S5a-c & Table S6). Consistent with inhibition of MacB due to disulfide locking, the 
Thr517Cys variant has a lower than wild type MIC that is further diminished by addition of CuCl2 (an 
oxidant favouring disulfide formation) and restored to wild type levels by DTT (favouring disulfide 
reduction). Contrastingly, the activities of the wild type, Glu170Gln and Thr517Ala variants are 
unaffected by either CuCl2 or DTT. The cysteine cross-linking experiment provides in vivo support for 
the mechanotransmission mechanism. 
 
A molecular bellows mechanism for the MacAB-TolC tripartite efflux pump. We considered how 
MacB mechanotransmission might operate within the context of the assembled MacAB-TolC pump to 
drive substrate from the periplasm to the extracellular space. The structure of the nucleotide-free 
MacAB-TolC complex is known (11) and superposition of our ATP-bound MacB structure suggests a 
model for the missing assembled state. The model suggests the MacA hexamer accommodates MacB 
in both of its two conformational states and that a tight seal between these components is maintained 
throughout the mechanotransmission cycle. An interior cavity at the interface between MacA and 
MacB undergoes dramatic changes in volume upon transition between nucleotide-free and ATP-bound 
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forms (SI Appendix, Fig. S6) leading us to suggest that the assembled MacAB-TolC complex acts as 
a ‘molecular bellows’ during efflux (SI Appendix, Fig. 5a, b).  
 
In the molecular bellows mechanism (SI Appendix, Fig. 5a, b), substrates are proposed to enter the 
interior cavity via an opening in MacB located between parted periplasmic domains and stalk (see also 
Fig. 4a, left) before subsequent ATP-binding causes closure of the periplasmic domain by 
mechanotransmission. The reduction in interior cavity volume forces the contents of the MacB 
periplasmic domain, under pressure, through the MacA gate ring, previously suggested to act as a one-
way valve (11). Once the pressure on either side of the gate has equalised, the gate ring relaxes to its 
closed resting state preventing backflow of substrates. ATP hydrolysis then resets the system with 
further substrates and solvent necessary to refill the cavity entering from the periplasm as the interior 
cavity expands. 
 
Coordination of the ATP-binding and hydrolysis cycle with detection of the substrate in the 
periplasmic cavity is likely to be regulated to prevent wasteful expenditure of ATP. Whether MacB 
has a role in sensing the ‘readiness’ of periplasmic-bound substrates for export is unclear, but it is 
known that the MacA N-terminus spans the inner membrane and stimulates MacB ATPase activity 
suggesting the adaptor plays a role in mediating this signal (5, 19). 
 
MacB represents a superfamily of mechanotransmissive ABC transporters including LolCDE 
and FtsEX. We next examined the degree to which structural features underpinning the 
mechanotransmission mechanism in MacB are conserved in related proteins. MacB belongs to a large 
and functionally-diverse monophyletic group of ABC transporters (sometimes termed the ABC3 
superfamily) that has been defined based on sequence-level features including hydropathy profiles and 
amino acid similarity (12, 13). Many homologues of MacB are genetically encoded in operons 
alongside genes for a periplasmic adaptor and TolC-like protein suggesting they form TEPs similar to 
MacAB-TolC. Two examples are PvdT of Pseudomonas aeruginosa (20) and AatP from 
enteroaggregative E. coli (21). Like MacAB-TolC, these TEPs extract their substrates from the 
periplasm and use cytoplasmic ATP hydrolysis to power efflux across the outer membrane. Other 
homologues of MacB do not form TEPs, but do couple cytoplasmic ATP hydrolysis with activities in 
the periplasm or extracytoplasmic space. LolC and LolE collaborate with NBDs encoded by LolD to 
translocate lipoproteins from the outer face of the inner membrane to a periplasmic chaperone during 
outer membrane biogenesis (14). Similarly, FtsE (NBD) and FtsX (transmembrane domain) form a 
substrateless ABC transporter involved in transmembrane signalling between cytoplasmic and 
periplasmic components of the cell division machinery (15, 22). Hydropathy plots show that PvdT, 
AatP, LolC, LolE and FtsX all have the same transmembrane topology as MacB, with a periplasmic 
domain located between the first and second membrane spanning helices (Fig. 6a). Secondary 
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structure analysis predicts that all these proteins except FtsX contain both the Porter and Sabre 
subdomains present in the MacB crystal structure (Fig. 6b). For FtsX, the presence of the Porter and 
absence of the Sabre is confirmed by its crystal structure from M. tuberculosis. However, our 
prediction for LolCDE conflicts with previous suggestions that the periplasmic domain may have a β-
barrel fold similar to LolA and LolB (23). Assigning the correct fold to LolC is essential because the 
previously proposed ‘mouth-to-mouth’ transfer of lipoprotein substrates from LolCDE to LolA is not 
compatible with a MacB-like fold. We experimentally tested our prediction by solving the crystal 
structure of the E. coli LolC periplasmic domain. Data collection and refinement statistics are 
provided in SI Appendix, Table S7 and the LolC periplasmic domain is shown in comparison with 
those of MacB and FtsX in Fig. 6c. The 1.88 Å structure of LolC confirms a MacB-like fold with both 
Sabre (Fig. 6d) and Porter (Fig. 6e) subdomains (Movie 4). We conclude that features of the MacB 
architecture underpinning its distinctive mechanotransmission mechanism, including transmembrane 
topology and core aspects of its extracytoplasmic domain structure, are conserved throughout this 
ABC superfamily. 
 
DISCUSSION 
We determined the crystal structure of MacB in an ATP-bound conformation revealing a new ABC 
transporter fold (Fig. 1) and discovered that MacB confers resistance to cyclic peptides such as 
bacitracin and colistin in addition to expelling the known substrates erythromycin and enterotoxin 
STII (Fig. 2). Structure-guided mutagenesis of MacB led to identification of residues in the 
periplasmic domain essential for erythromycin tolerance (Fig. 3) and comparison of ATP-bound and 
nucleotide-free structures of MacB revealed allosteric coupling of periplasmic conformational change 
with reversible dimerization of the cytoplasmic NBDs (Fig. 4). We term the distinctive 
transmembrane conformational coupling mechanism of MacB ‘mechanotransmission’ and propose 
that it is harnessed within the context of the assembled tripartite efflux pump to drive substrate efflux 
from the periplasm to the extracellular space by acting as a ‘molecular bellows’ (Fig. 5). Finally, we 
demonstrate that the structural architecture underlying mechanotransmission is present in homologous 
systems such as the LolCDE lipoprotein trafficking complex and FtsEX cell division machinery 
(Fig. 6) suggesting a unified mechanism for the entire superfamily. 
 
The key feature of MacB that distinguishes it from other ABC transporters is its mechanotransmission 
mechanism (Fig. 4, Movie 3). Neither ATP-bound nor nucleotide-free structures of MacB reveal 
evidence of a central pore through which substrates might be passed, nor does either exhibit the 
characteristic inward- and outward-facing cavities that are the hallmark of alternating-access 
mechanism. MacB operates solely through extracytoplasmic conformational change driven by 
cytoplasmic ATP hydrolysis. In collaboration with the MacA adaptor and TolC exit duct, MacB 
powers the expulsion of enterotoxin STII from periplasm to extracellular space and it seems likely that 
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antibiotic substrates of MacB (erythromycin, colistin and bacitracin) take the same route, rather than 
being driven across the inner membrane as previously thought. Alternatively, it is possible that MacB 
does not interact directly with antibiotics, but instead transports another, as-yet-unidentified factor 
affecting the cell’s susceptibility. Outer membrane glycolipids have been implicated as potential 
substrates for MacAB-TolC (24), and such substrates could conceivably drive resistance indirectly by 
modifying permeability of the cell envelope. 
 
MacB’s role in erythromycin resistance partially overlaps that of the RND family tripartite efflux 
pump AcrAB-TolC. RND family TEPs, including AcrAB-TolC, have been described as ‘periplasmic 
vacuum cleaners’ (25) on account of their broad substrate specificity. While AcrAB-TolC is highly 
proficient in secretion of small molecules, including erythromycin, enterotoxin STII is solely exported 
via MacAB-TolC. Systems homologous to MacAB-TolC secrete pyoverdine (a peptide-like 
siderophore from P. aeruginosa (20)) and dispersin (a 10 kDa enteroaggregative E. coli signalling 
protein (21)) which suggests a division of labour where RND transporters tackle small molecule efflux 
and MacAB-TolC-based systems drive export of larger peptides and small proteins.  
 
The structural architecture of MacB is conserved in both FtsEX and LolCDE (Fig. 6) suggesting the 
capacity for mechanotransmission is also preserved. FtsEX regulates periplasmic peptidoglycan 
hydrolases during cell division (15, 22, 26) while LolCDE extracts lipoproteins from the outer-leaflet 
of the bacterial inner membrane and presents them to the periplasmic chaperone LolA for trafficking 
to the outer membrane (14, 27). Roles for mechanotransmission in these processes remain to be fully 
elucidated, however, for LolCDE, the upward force generated by zipping together of the periplasmic 
stalk could aid lipoprotein extraction from the bacterial membrane. Similarly, for FtsEX, the two 
conformational states could form a molecular switch, stimulating recruitment and/or activation of 
extracytoplasmic enzymes in one conformation and frustrating this process in the other. The MacB 
structures constitute a valuable tool for guiding future research on FtsEX and LolCDE both of which 
are key antibiotic targets (28, 29). 
 
Intriguingly, the LptBFG complex has a similar function to LolCDE but an entirely different 
transmembrane topology (30). The use of several distinct structural folds to direct similar in vivo 
functions is a recurring feature of ABC transporter evolution as evidenced by the three different ABC 
superfamilies linked to substrate import (SI Appendix, Fig. S1 - Types I, II and III) and further two 
associated with substrate export (SI Appendix, Fig. S1 - Types IV and V). It will be interesting to 
compare the mechanism of MacB/LolCDE (Type VII) with that of LptBFG (Type VI) once further 
conformational states of the latter are known. 
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In summary, the MacB structure defines a new ABC transporter superfamily and reveals the 
mechanotransmission mechanism it uses. MacB superfamily members do not transport substrates 
across the inner membrane in which they reside, but instead, couple cytoplasmic ATP hydrolysis to 
extracytoplasmic conformational change. Whether mechanotransmission is used to gate access to an 
outer membrane exit duct (as for MacB), pass a substrate from the membrane to a chaperone 
(LolCDE), or else regulate the activity of periplasmic enzymes (FtsEX), the same underlying 
4-transmembrane helix architecture provides the means of transmitting conformational change across 
the membrane. The MacB architecture provides a fresh structural and mechanistic perspective on a 
plethora of homologous ‘mechanotransmissive ABC transporters’ that mediate diverse biological 
functions in the bacterial envelope and extracellular space. 
 
METHODS 
Detailed Supplementary Methods are available online. Briefly, Aggregatibacter actinomycetemcomitans MacB 
was expressed with an N-terminal His-tag in E. coli C43 (DE3) before purification in lauryl maltose neopentyl 
glycol as a stabilising detergent. MacB was crystallised in two distinct crystal forms in the presence of either 
ATPγS or ATP and the structures solved by a combination of molecular replacement and selenomethionine 
phasing methods. Structures of the E. coli MacB periplasmic domain (residues 309-508) and cytoplasmic NBD 
(residues 1-223) were determined to aid this phasing strategy. Minimum inhibitory concentrations were assessed 
by serial dilution method in E. coli C43ΔacrABΔmacAB with either wild type or variant MacB co-expressed 
with MacA from a plasmid. Enterotoxin STII secretion was assessed by trichloroacetic acid precipitation of 
culture supernatants and analysed by SDS-PAGE. Molecular morphs used a homology model of E. coli MacB 
based on the A. actinomycetemcomitans ATP-bound state and the nucleotide-free state extracted from 5NIL (11) 
as start and end points. Bioinformatic analysis used TMPred for hydropathy plots and Promals3D (31) for 
secondary structure prediction and sequence alignment. The E. coli LolC periplasmic domain (residues 48-266) 
was expressed with a C-terminal His-tag in E. coli BL21 (DE3) and the structure solved by molecular 
replacement using the AaMacB periplasmic domain. All structures were deposited in protein databank: accession 
codes 5LIL, 5LJ6, 5LJ7, 5LJ8, 5LJ9, 5LJA and 5NAA. 
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FIGURES 
 
 
 
 
Figure 1: Crystal structure of A. actinomycetemcomitans MacB with bound ATP. (a) Overall 
structure of the MacB dimer. (b) Linear domain organisation of the MacB polypeptide. (c) Topology 
of MacB. (d) Location of the two ATP molecules (yellow) clamped between the nucleotide binding 
domains (NBDs). (e) Detailed view of bound ATP with omit map density contoured at 3.5 sigma 
(teal). Residues interacting with ATP are labelled and potential hydrogen bonds (dashed yellow lines) 
are indicated. Colouring is consistent across the figure, one monomer is shown in grey and the second 
is coloured according to the domain arrangement. 
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Figure 2: Functional analysis of E. coli MacAB-TolC in vivo. (a) Antibiotic susceptibility 
comparison between E. coli C43 (DE3) ΔacrABΔmacAB cells expressing E. coli MacA and either 
wild type or Glu170Gln E. coli MacB variant. The ratio of the MIC for the wild type MacB to the 
Glu170Gln variant is shown graphically for ethidium bromide (EBR), chlorhexidine (CHX), SDS, 
gentamycin (GEN), tetracycline (TET), ciprofloxacin (CIP), chloramphenicol (CHL), kanamycin 
(KAN), colistin (COL), bacitracin (BAC) and erythromycin (ERY). Structures of erythromycin, 
bacitracin and colistin are shown inset. (b) Structure of enterotoxin STII with disulfide bond-forming 
sulfur atoms (yellow spheres) (PDB: 1EHS) (32). (c) Detection of secreted enterotoxin in E. coli 
culture supernatants by SDS-PAGE. Lanes from left to right, C43 wild type, C43ΔmacAB, 
C43ΔmacAB expressing plasmid-borne macA (A), macB (B), macAB (AB), or macAB with an ATPase 
inactivating Glu170Gln substitution (EQ). All strains contain a plasmid expressing enterotoxin STII. 
(d) Model for two-step secretion of enterotoxin STII across the E. coli cell envelope. Sec and Dsb 
represent the general protein secretion machinery and disulfide bond incorporation systems, 
respectively. 
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Figure 3: Structure-based mutational analysis of E. coli MacB. Erythromycin resistance of C43 
(DE3) ΔacrAB ΔmacAB cells expressing E. coli MacA and variant MacB mapped to a model of one 
monomer of E. coli MacB. Key indicates the fold decrease in MIC relative to cells expressing wild 
type MacAB. (a) The MacB monomer presenting the dimer interface. (b) Close-up view of the 
periplasmic domain. (c) Top-down view of the MacB periplasmic domain. (d) Minimum inhibitory 
concentrations (MICs, µg/ml) for the 70 MacB variants tested. Homology model shown is based on 
our full-length A. actinomycetemcomitans MacB crystal structure and high-resolution structure of the 
E. coli MacB periplasmic domain. 
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Figure 4: Mechanotransmission mechanism of MacB. (a) Nucleotide-free (left) and ATP-bound 
MacB (right). (b) Top-down view of the MacB dimer showing the open head of the nucleotide-free 
form. (c) Equivalent view of the ATP-bound form showing closure of the periplasmic dimer. Domains 
of MacB coloured as in Figure 1. Both models represent E. coli MacB, the nucleotide-free form is 
extracted from the cryoEM structure of the MacAB-TolC complex (5NIL) and the ATP-bound form is 
a homology model generated from our crystal structure of the nucleotide-bound A. 
actinomycetemcomitans MacB (5LIL). A full molecular morph between the two states is presented in 
Movie 3. 
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Figure 5: A ‘molecular bellows’ mechanism for substrate secretion by the MacAB-TolC 
tripartite efflux pump. (a) Proposed catalytic cycle of the MacAB-TolC efflux pump. MacB (red), 
MacA (purple), TolC (green) and substrate (blue). (b) Operation of a fireplace bellows. 
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Figure 6: MacB is the archetypal member of a topological unique ABC superfamily. (a) 
Hydropathy profile of MacB and five key homologues demonstrating a common 4-transmembrane 
helix topology. Horizontal bars above the plots indicate TM helices. (b) Comparison of secondary 
structure predictions for the periplasmic domain located between TM1 and TM2 for MacB and 
homologues. Beta sheets (blue), alpha helices (red) and alignment gaps (grey) are shown. (c) 
Periplasmic domain structures of MacB, LolC and FtsX. Sabre subdomain shown in purple, Porter 
subdomain cyan. (d) Superposition of Sabre subdomains from MacB and LolC. (e) Superposition of 
Porter subdomains from MacB, LolC and FtsX. 
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Supplemental Figures 
 
Figure S1: Seven ABC transporter superfamilies. ABC transporters of known structure fall into 
seven distinct superfamilies that are readily discerned by their 3-dimensional fold. An example from 
each superfamily is presented. From left to right the molybdate transporter (1) (ModABC), vitamin B12 
transporter (2) (BtuCDF), folate importer (3) (EcfAST), multidrug exporter (4) (Sav1866), the sterol 
transporter (5) (ABCG5/G8), LPS extractor (6) (LptBFG) and the enterotoxin and macrolide 
transporter (MacB). Folds are named by extension of a previously established convention (7). PDB 
codes are shown in parentheses.  
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Figure S2: Intramembrane cavity analysis for ABC transporter superfamilies. (a) Visualisation 
of central transmembrane cavities as solid red ‘casts’ produced using HOLLOW (8). Sav1866 (4) and 
BtuCDF (2) are in outward-facing conformations, ModABC (1) and ABCG5/G8 (5) are both inward 
facing. MacB does not possess any significant cavities in either the transmembrane domain or 
periplasmic stalk. (b) Plots of cavity diameter at 3 Å intervals across the membrane region, from 
cytoplasm (-30 Å) to periplasm (+30 Å), are shown for MacB and five other ABC transporters. The 30 
Å hydrophobic membrane core is shaded orange (-15 Å to +15 Å) with the lipid head group region in 
a lighter tone. The horizontal line represents the diameter of a water molecule (2.75 Å), only the 
region above the horizontal dotted line is solvent accessible. Analysis used the PoreWalker server (9). 
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Figure S3: MacB periplasmic domain variants impaired in erythromycin tolerance have similar 
impairments in bacitracin and colistin resistance. (a) Comparison of bacitracin MIC data with 
erythromycin. (b) Comparison of colistin MIC data with erythromycin. Coloured bars represent fold 
increase in median MIC using the E170Q variant as the reference. Full details of the MIC data are 
provided in Table S5. 
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Figure S4 
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Figure S4: Dimer interfaces for ATP-bound and nucleotide-free MacB. (a) Face-on view of the 
interface for a monomer of an E. coli MacB homology model based on the ATP-bound 
A. actinomycetemcomitans MacB structure. (b) Equivalent view of a monomer from E. coli MacB 
extracted from the cryoEM structure of the MacAB-TolC assembly (5NIL). Residues at the interface 
were identified with PISA (10) and contact sites defined using a 5 Å cut-off. Contact residues 
belonging to either TM1 or TM2 are coloured blue, and contacts elsewhere are coloured red. Residues 
belonging to TM1 or TM2 are annotated in bold with residues they contact across the dimer interface 
noted beneath in plain font. For clarity, residues falling on the same ‘rung’ of a helix are noted side-
by-side with a single marker drawn to locate that rung on the structure.  
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Figure S5: Locking the MacB periplasmic stalk using cysteine disulfide cross-links. (a) Location 
of Thr517 in nucleotide-free (top) and ATP-bound MacB (bottom). (b) Top-down view of the stalk 
showing position of Thr517 in the dimer interface. (c) MacB activity assessed using erythromycin 
MIC data. Coloured bars represent median values with the interquartile range shown as a black line.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 7	
 
 
 
 
 
 
 
 
Figure S6: Volumetric analysis of the MacAB-TolC assembly. A central cavity at the interface 
between MacA and MacB undergoes a significant decrease in volume upon closure of the MacB 
periplasmic domains during ATP-binding. Models of the assembly in nucleotide-free and ATP-bound 
forms are shown on the left and right, respectively. Cavities are shown as solid casts with colour-
coded volumes indicated alongside. TolC is omitted for clarity. 
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Supplemental Tables 
 
Table S1: Crystallographic data and refinement statistics for soluble domain structures of E. coli MacB 
 Periplasmic  
domain 
Cytoplasmic NBD  
(form I) 
Cytoplasmic NBD 
(form II) 
    
PDB code 5LJ8 5LJ9 5LJA 
    
Data collection    
Beam line DLS I24 DLS I24 DLS I24 
Wavelength (Å) 0.96861 0.96861 0.96862 
    
Crystal parameters    
Space group P21 P6122 C2221 
Unit cell dimensions (Å) 50.1, 54.9, 66.9 56.0, 56.0, 259.1 57.5, 96.2, 262.7 
Unit cell angles (°) 90, 92.9, 90 90, 90, 120 90, 90, 90 
Mosaic spread (°) 0.68 0.43 0.50 
    
Reflection data *    
Resolution range (Å) 32.87-1.95 (2.00-1.95) 48.48-2.40 (2.49-2.40) 52.54-2.30 (2.38-
2.30) 
Unique reflections 26,585 (1,874) 10,332 (1,044) 31,381 (2,615) 
Rsym 0.089 (0.542) 0.096 (0.820) 0.077 (0.431) 
I/σ(I) 8.1 (1.9) 12.2 (1.8) 14.0 (4.9) 
CC½  0.99 (0.70) 1.00 (0.69) 0.998 (0.92) 
Completeness (%) 99.8 (99.7) 100.0 (100.0) 95.2 (82.4) 
Multiplicity 3.4 (3.2) 7.6 (4.9) 6.6 (6.3) 
Wilson B (Å2) 21.5 39.8 31.8 
    
Refinement †    
Resolution (Å) 66.8 – 1.95 48.48 – 2.40 52.54-2.30 
Number of reflections 25,260 9,759 29,723 
Rwork 0.178 0.223 0.186 
Rfree 0.228 0.297 0.225 
Rms (bond lengths) (Å) 0.017 0.013 0.016 
Rms (bond angles) (°) 1.66 1.73 1.73 
    
Model composition    
Protein atoms 3,266 1,801 5,450 
Waters 99 9 199 
    
Model B-factors    
Protein atoms (Å2) 25.8 56.1 39.4 
Waters (Å2) 29.4 48.9 36.6 
    
Ramachandran statistics ‡    
Favoured (%) 99.0 97.4 97.9 
Allowed (%) 0.8 2.6 2.1 
Outliers (%) 0.3 0.0 0.0 
    
* As reported by Aimless (19).  
†
 As reported by Refmac (26). 
‡ As reported by Rampage (28). 
Values in parentheses indicate the outer resolution bin. 
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Table S2: Crystallographic data and refinement statistics for A. actinomycetemcomitans MacB 
 Seleno-MacB 
Hexagonal 
MacB 
Hexagonal 
MacB 
Monoclinic I 
MacB 
Monoclinic II 
     
PDB code - 5LJ6 5LIL 5LJ7 
     
Data collection     
Beam line DLS I24 DLS I24 Soleil PX2 DLS I24 
Wavelength (Å) 0.91732 0.97943 0.9763 0.96861 
     
Crystal parameters     
Space group P6522 P6522 P21 P21 
Unit cell dimensions (Å) 119.01, 119.01, 
300.87 
119.57, 199.57, 
307.78 
111.59, 82.62, 
124.92 
112.33, 82.61, 
125.17 
Unit cell angles (°) 90, 90, 120 90, 90, 120 90, 94.45, 90 90, 93.54, 90 
Mosaic spread (°) 0.63 0.80 0.98 0.71 
Number of crystals 1 1 3 1 
     
Reflection data *     
Resolution range (Å) 60.17-5.00 
[60.17-11.18] 
(5.59-5.00) 
61.56-3.90 
[61.56-8.72] 
(4.36-3.90) 
79.95-3.35 
[79.95-10.59] 
(3.53-3.35) 
86.13-3.25 
[86.13-11.26] 
(3.39-3.25) 
Unique reflections 5,997 [635] 
(1,624) 
12,392 [1,297] 
(3,286) 
32,862 [1,110] 
(4,631) 
36,201 [901] 
(4,429) 
Rsym 0.145 [0.052] 
(1.792) 
0.103 [0.051] 
(2.466) 
0.284 [0.064] 
(1.522) 
0.210 [0.071] 
(1.317) 
Rmeas 0.152 [0.057] 
(1.842) 
0.108 [0.053] 
(2.585) 
0.301 [0.069] 
(1.617) 
0.230 [0.078] 
(1.436) 
Rpim 0.028 [0.011] 
(0.324) 
0.029 [0.015] 
(0.651) 
0.099 [0.026] 
(0.541) 
0.092 [0.033] 
(0.565) 
I/σ(I) 16.1 [49.7] (3.1) 10.3 [36.5] (1.8) 7.7 [28.4] (2.1) 6.7 [17.6] (1.7) 
CC½  1.00 (0.388) 0.997 (0.652) 0.993 (0.790) 0.995 (0.799) 
Completeness (%) 100.0 [99.5] 
(100.0) 
97.9 [99.8] 
(94.8) 
99.6 [99.8] 
(97.1) 
99.4 [96.6] 
(99.9) 
Multiplicity 31.3 [26.2] 
(32.2) 
13.8 (13.0) 9.3 (8.9) 6.1 (6.2) 
Wilson B (Å2) 291 215 125 38 
     
Refinement †     
Resolution (Å) - 59.79-3.90 79.95-3.35 86.13-3.25 
Reflections - 12,315 32,620 36,080 
Rwork - 0.2675 0.2444 0.2447 
Rfree - 0.3222 0.2902 0.2994 
Rms (bond lengths) (Å) - 0.004 0.003 0.003 
Rms (bond angles) (°) - 1.025 0.711 0.637 
     
Model composition     
MacB - 1 2 2 
ATP - 1 2 2 
Mg2+  1 2 2 
Waters - - 4 4 
     
Model B-factors     
MacB (Å2) - 239 100 103 
ATP/Mg2+ (Å2) - 225 70 75 
Waters (Å2) - 159 56 55 
     
Ramachandran statistics ‡     
Favoured (%) - 91.69 93.84 93.14 
Allowed (%) - 7.63 5.75 6.60 
Outliers (%) - 0.68 0.42 0.26 
     
* As reported by Aimless (19).  
†
 As reported by Refmac (26). 
‡ As reported by Rampage (28). 
Values in parentheses indicate the outer resolution bin. 
Values in square brackets indicate the inner resolution bin..
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Table S3: Antimicrobial susceptibility testing. MIC expressed as µg/mL. 
 
 
Antimicrobial Num. repeats Mean±SD MIC Median±SIQR MIC 
 WT E170Q WT E170Q WT E170Q 
Erythromycin (ERY) 24 24 31±3 1±0 32±8 1±0 
Bacitracin (BAC) 24 24 8021±836 490±72 8192±0 512±0 
Colistin (COL) 32 32 23±8 4±1 16±4 4±0 
Kanamycin (KAN) 8 8 32±0 18±6 32±0 16±0 
Chloramphenicol (CHL) 8 8 1±1 1±1 1±1 1±0 
Ciprofloxacin (CIP) 8 8 1±0 1±0 1±0 1±0 
Tetracycline (TET) 8 8 2±0 2±0 2±0 2±0 
Gentamycin (GEN) 3 3 15±2 16±0 16±0 16±0 
Sodium dodecyl sulphate (SDS) 8 8 >256 >256 >256 >256 
Chlorhexidine (CHX) 8 8 2±0 2±1 2±1 2±0 
Ethidium bromide (EBR) 8 8 2±0 2±0 2±0 2±0 
 
Minimum Inhibitory Concentrations (MICs) expressed as µg/mL. 
Mean±SD corresponds to the arithmetic mean ± standard deviation. 
Median±SIQR corresponds to the median value ± semi-interquartile range. 
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Table S4: Erythromycin MIC data for wild type and variant MacB 
 
 
Variant Repeats Mean±SD MIC 
Median±SIQR 
MIC Location STII export 
WT 32 40±15 32±4 - + 
Control 32 1±1 1±0.5 - - 
 K47A 24 1±1 1±0.5 NBD - 
R121A 24 7±2 8±2 NBD + 
E170Q 24 1±0 1±0 NBD - 
E256A 24 24±14 16±8 Amphipathic helix + 
T275A 24 8±0 8±0 TM1 + 
S285A 24 22±8 16±8 TM1 + 
T311A 24 29±11 32±8 Porter I + 
D313A 24 21±8 16±8 Porter I + 
Y315A 24 6±2 4±2 Porter I + 
K318A 24 14±5 16±4 Porter I + 
D319A 24 7±3 8±2 Porter I + 
F320A 24 3±1 4±1 Porter I + 
D322A 24 13±4 16±4 Porter I + 
D323A 24 11±4 8±4 Porter I + 
D324A 24 19±10 16±12 Porter I + 
Q326A 24 32±0 32±0 Porter I + 
Y327A 24 16±8 16±4 Porter I + 
Q328A 24 32±0 32±0 Porter I + 
Q329A 24 28±7 32±2 Porter I + 
N335A 24 33±7 32±0 Porter I + 
T349A 24 2±1 2±0 Porter I + 
S353A 24 22±8 16±8 Sabre + 
N355A 24 21±8 16±8 Sabre + 
R357A 24 11±4 8±4 Sabre + 
R359A 24 13±4 16±4 Sabre + 
N361A 24 27±7 32±8 Sabre + 
N362A 24 28±11 32±8 Sabre + 
D364A 24 22±8 16±8 Sabre + 
S368A 24 14±4 16±1 Sabre + 
N370A 24 27±8 32±8 Sabre + 
V372A 24 15±6 16±1 Sabre + 
Y376A 24 1±0 1±0 Sabre + 
D405A 24 21±8 16±8 Sabre + 
S406A 24 27±8 32±8 Sabre + 
N407A 24 13±4 16±4 Sabre + 
R409A 24 27±8 32±8 Sabre + 
R410A 24 14±4 16±4 Sabre + 
Q411A 24 43±22 48±24 Sabre + 
N428E 24 84±32 64±32 Sabre + 
E438A 24 43±15 32±16 Sabre + 
E439A 24 41±17 32±16 Sabre + 
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K440A 24 8±6 8±2 Sabre + 
Q441A 24 27±8 32±8 Sabre + 
S442A 24 9±3 8±0 Sabre + 
M443A 24 7±3 8±2 Sabre + 
F444A 24 2±1 2±0.5 Sabre + 
S446A 24 21±7 16±8 Sabre + 
S447A 24 8±2 8±0 Sabre + 
K448A 24 32±0 32±0 Sabre + 
R451A 24 9±3 8±0 Sabre + 
W453A 24 32±16 32±8 Sabre + 
Y456A 24 26±8 32±8 Sabre + 
R462E 24 43±15 32±16 Sabre + 
S471A 24 11±4 8±4 Porter II + 
T473A 24 21±8 16±8 Porter II + 
E486A 24 7±6 4±2 Porter II + 
H497A 24 32±23 32±8 Porter II + 
K499A 24 27±8 32±8 Porter II + 
K500A 24 52±16 64±16 Porter II + 
D501A 24 21±8 16±8 Porter II + 
F503A 24 4±1 4±0 Porter II + 
W505A 24 2±1 2±0 Porter II + 
M507A 24 3±1 3±1 Porter II + 
T517A 24 87±33 64±32 Stalk + 
T520A 24 64±46 32±48 Stalk + 
S532A 24 30±15 32±8 TM2 + 
N542A 24 32±0 32±0 TM2 + 
D322A+D323A+D324A 24 4±1 4±0 Porter + 
Y376A+F444A 24 1±0 1±0 Sabre + 
E438A+E439A 24 43±15 32±16 Sabre + 
Δ C-terminus 24 8±4 8±2 Minor coupling helix + 
 
Minimum Inhibitory Concentrations (MICs) expressed as µg/mL. 
Mean±SD corresponds to the arithmetic mean ± standard deviation. 
Median±SIQR corresponds to the median value ± semi-interquartile range. 
The MacB periplasmic domain is made up of both Porter and Sabre subdomains. The Porter itself is formed from 
two discontinuous regions of primary sequence labelled here as Porter I and Porter II. 
Abbreviations used: NBD, Nucleotide binding domain; TM1 and TM2, transmembrane helix 1 and transmembrane 
helix 2. 
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Table S5: Bacitracin and Colistin MIC data for MacB variants. 	
 Bacitracin Colistin  
Variant N Mean±SD  Median±SIQR  N Mean±SD Median±SIQR Location 
WT 24 4096±0 4096±0 24 16±0 16±0 - 
Control 24 277±72 256±0 24 6±2 4±2 - 
K47A 24 256±0 256±0 24 6±2 4±2 NBD 
E170Q 24 251±26 256±0 24 5±2 4±2 NBD 
D313A 24 4096±0 4096±0 24 8±2 8±0 Porter I 
T349A 24 2048±0 2048±0 24 10±5 8±6 Porter I 
N355A 24 4096±0 4096±0 24 18±11 16±12 Sabre 
Y376A 24 331±118 256±0 24 6±2 8±2 Sabre 
N407A 24 3413±986 4096±1024 24 11±4 8±4 Sabre 
F444A 24 491±72 512±0 24 6±2 6±2 Sabre 
W505A 24 1024±0 1024±0 24 7±2 8±2 Porter II 
Y376A+ 
F444A 24 352±127 256±128 24 5±2 4±2 Sabre 
 
Minimum Inhibitory Concentrations (MICs) expressed as µg/mL. 
N = number of repeats. 
Mean±SD corresponds to the arithmetic mean ± standard deviation. 
Median±SIQR corresponds to the median value ± semi-interquartile range. 
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Table S6: Cysteine-locking experiment MIC data. 
 
 - + Cu(II)Cl2 +DTT 
Variant N Mean ±SD  
Median 
±SIQR  N 
Mean 
±SD 
Median 
±SIQR N 
Mean 
±SD 
Median 
±SIQR 
WT 24 43±15 32±16 24 32±0 32±0 24 43±15 32±16 
E170Q 24 1±1 1±1 24 2±1 1±1 24 1±0 1±0 
T517A 16 64±0 64±0 16 62±8 64±0 16 64±0 64±0 
T517C 16 16±0 16±0 16 5±2 4±1 16 46±21 64±18 
 
Minimum Inhibitory Concentrations (MICs) for erythromycin expressed as µg/mL. 
N = number of repeats. 
Mean±SD corresponds to the arithmetic mean ± standard deviation. 
Median±SIQR corresponds to the median value ± semi-interquartile range. 
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Table S7: Crystallographic data and refinement statistics for the periplasmic domain of E. coli LolC 
 
 Periplasmic domain 
of E. coli LolC 
  
PDB code 5NAA 
  
Data collection  
Beam line I03 
Wavelength (Å) 0.9763 
  
Crystal parameters  
Space group C2 
Unit cell dimensions (Å) 54.7, 111.8, 75.9 
Unit cell angles (°) 90, 109, 90 
Mosaic spread (°) 0.84 
  
Reflection data *  
Resolution range (Å) 45.99-1.88 (1.92-1.88) 
Unique reflections 34,822 (2,179) 
Rsym 0.078 (0.436) 
I/σ(I) 11.0 (2.4) 
CC½  0.996 (0.759) 
Completeness (%) 99.5 (98.1) 
Multiplicity 5.1 (3.9) 
Wilson B (Å2) 24.8 
  
Refinement †  
Resolution (Å) 45.99 (1.88) 
Number of reflections 32,931 
Rwork 0.1798 
Rfree 0.2252 
Rms (bond lengths) (Å) 0.018 
Rms (bond angles) (°) 1.81 
  
Model composition  
Protein atoms 3,467 
Waters 240 
Other 5 
  
Model B-factors  
Protein atoms (Å2) 32.9 
Waters (Å2) 37.0 
Other 60.2 
  
Ramachandran statistics ‡  
Favoured (%) 98.4 
Allowed (%) 1.6 
Outliers (%) 0.0 
  
 
* As reported by Aimless(19).  
†
 As reported by Refmac (26). 
‡ As reported by Rampage (28). 
Values in parentheses indicate the outer resolution bin. 
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Supplementary Methods 
 
Construction of strains and plasmids 
pET28-EcMacB, encoding N-terminally His-tagged E. coli MacB, was created by PCR amplification 
of macB from E. coli MG1655 genomic DNA, digestion with NdeI and BamHI, and ligation into 
pET28 (Novagen) digested with the same enzymes. MacB homologues from 
A. actinomycetemcomitans, A. pleuropneumoniae, P. aeruginosa, P. syringae, R. capsulatus, 
S. marcescens, S. typhimurium and P. mirabilis were cloned with a similar strategy. 
A. actinomycetemcomitans E169Q and E. coli E170Q MacB mutants were introduced by Quikchange 
site-directed mutagenesis. Plasmids expressing the E. coli MacB NBD (pMacB-NBD; residues 1-223) 
and the periplasmic domain (pMacB-Peri; residues 309-508) with C-terminal His-tags were created by 
PCR amplification of E. coli MG1655 genomic DNA, digestion of PCR products with NdeI and XhoI, 
and ligation into pET21a digested with the same enzymes. E. coli macA was cloned NdeI-XhoI into 
the second multiple cloning site (MCS) of pETDuet1 (Novagen) resulting in pDuet-MacA. For co-
expression of E. coli MacAB, wild type macB was cloned NcoI-HindIII into the first MCS of pET-
MacA resulting in pETDuet-MacAB. Point mutants were introduced into pETDuet-MacAB by 
Quikchange site-directed mutagenesis. Heat stable enterotoxin was amplified from pET11-STII (11) 
and cloned into pCDFDuet using NcoI and KpnI restriction sites resulting in pCDF-STII. The E. coli 
LolC periplasmic domain predicted by Octopus (12) (residues 48-266) was amplified from E. coli 
MG1655 genomic DNA, digested with NdeI and NotI and ligated into pET24 digested with the same 
enzymes resulting in pET24-EcperLolC. All clones were verified by DNA sequencing (Source 
Bioscience). The macAB locus in E. coli C43 (DE3) (13) was replaced with a kanamycin resistance 
cassette using the λ Red recombinase system (14). The resistance cassette was subsequently removed 
by transformation with plasmid pCP20 encoding the FLP recombinase (15) resulting in strain C43 
(DE3) ∆macAB. Strain C43 (DE3) ∆acrAB ∆macAB was created by subsequent removal of acrAB in 
the same manner. Both deletions were confirmed by PCR of the gene locus.  
 
Enterotoxin secretion assay 
C43 (DE3) or C43 (DE3) ∆macAB bearing pCDF-STII and plasmid-borne mac genes as indicated 
were grown in 2YT medium at 37 °C until an OD600 of 0.4 was achieved. Protein production was 
induced with 0.5 mM IPTG and cultures grown for a further 2 hours. Cells were removed by 
centrifugation at 4000 g and the supernatant passed through a 0.22 µm filter. Supernatant samples 
(1 mL) were precipitated with 10 % trichloroacetic acid (final concentration), washed with acetone 
and then resuspended in SDS-PAGE loading buffer before analysis by SDS-PAGE on 10 % Bis-Tris 
gels. Identity of STII enterotoxin was confirmed by mass spectrometry (PNAC, University of 
Cambridge). 
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Minimum inhibitory concentration (MIC) determinations 
C43 (DE3) ∆acrAB ∆macAB bearing pETDuet MacAB wild type or variant were induced with 0.2 
mM IPTG for 1 hour before addition to wells of a 96 well plates containing 0.2 mM IPTG, 100 µg/ml 
carbenicillin and 2-fold serial dilution of the indicated drug in LB medium (final volume 180 µl per 
well). Dilutions were from a 1024 µg/ml stock for ethidium bromide, chlorhexidine, SDS, gentamycin, 
tetracycline, ciprofloxacin, kanamycin, colistin, erythromycin, 8192 µg/ml for bacitracin and 512 
µg/ml for chloramphenicol. For disulfide crosslinking experiments, 0.2mM CuCl2 or 2mM DTT were 
added as indicated. MICs were assessed after 16 hours growth at 30 ºC. Experiments were repeated at 
least 3 times. 
 
 
Purification of full-length A. actinomycetemcomitans MacB 
E. coli C43 (DE3) transformed with pET28-AaMacB was grown in 2YT medium at 30 °C. At OD600 
0.5, the temperature was reduced to 18 °C and protein expression induced by addition of 0.4 mM 
IPTG. After 16 hours further growth, cells were harvested by centrifugation (6000 g) and the cell 
pellets resuspended in 50 mM HEPES pH 7.5, 200 mM NaCl supplemented with protease inhibitor 
cocktail (Roche) and broken by 2 passages through a Constant Systems cell disruptor at 30000 psi. 
Unbroken cells and debris were removed by centrifugation (10 mins, 18000 g) before membranes 
were collected by centrifugation at 150000 g for 1 hour at 4 °C. Membranes were resuspended in 
25 mM HEPES pH 7.5, 150 mM NaCl, 10 % (v/v) glycerol supplemented with protease inhibitors and 
solubilised by addition of lauryl maltose neopentyl glycol (LMNG; 1 % (w/v) final concentration). 
Insoluble material was removed by centrifugation (45 mins, 150000 g) and the solubilised membranes 
added to IMAC resin (Biorad Profinity). The resin was washed with 25 mM HEPES pH 7.5, 500 mM 
NaCl, 0.03 % LMNG, 10 mM imidazole and eluted with 25 mM HEPES pH 7.5, 500 mM NaCl, 
0.03 % LMNG, 250 mM imidazole. Protein was buffer exchanged into 25 mM HEPES pH 7.5, 150 
mM NaCl, 0.02 % LMNG and concentrated using Amicon Ultra 15 centrifugal concentrators (100 
kDa cut-off). Selenomethionine incorporated AaMacB was produced using a metabolic inhibition 
protocol (16). C43 (DE3) cells bearing pET28-AaMacB plasmid were grown at 37 °C to OD600 0.5 in 
M9 minimal media supplemented with 50 µg/mL kanamycin, 0.2 % (w/v) glucose, 2 mM MgSO4, 0.1 
mM CaCl2 and 0.001 % (w/v) thiamine. 100 mg/L of threonine, lysine and phenylalanine, 50 mg/L of 
leucine, isoleucine and valine and 60 mg/L of selenomethionine were added and cells grown for a 
further 45 minutes. Protein expression was induced with 0.5 mM IPTG and the cells grown for a 
further 16h at 18 °C. Selenomethionine labelled protein was purified as native with the addition of 1 
mM TCEP to all buffers. Incorporation of selenomethionine residues was confirmed by mass-
spectrometry.  
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Purification of MacB periplasmic and cytoplasmic domains 
E. coli C43 (DE3) cultures bearing pMacB-NBD or pMacB-Peri were grown at 37 °C on 2YT media 
supplemented with 50 µg/mL carbenicillin. Protein expression was induced with 1 mM IPTG at an 
OD600 ~0.6 and the temperature reduced to 18 °C. After 16 hours further growth, cells were harvested 
by centrifugation and the pellets frozen at -80 °C. Thawed cell pellets were resuspended in IMAC 
wash buffer (50 mM HEPES pH 7.5, 300 mM NaCl, 25 mM imidazole), and lysed by passage through 
a Constant Systems Cell Disruptor (30200 psi). Lysate was centrifuged at 30000 g for 30 min at 6 °C 
to remove cellular debris and the supernatant loaded onto an immobilised Ni-affinity column pre-
equilibrated with the wash buffer (25 mM HEPES pH 7.5, 300 mM NaCl, 25 mM imidazole). Bound 
proteins were washed with 15 column volumes of wash buffer before elution in 50 mM HEPES pH 
7.5, 300 mM NaCl, 300 mM imidazole. Protein samples were exchanged into 20 mM HEPES pH 7.2, 
150 mM NaCl and concentrated to ~10 mg/mL using a centrifugal filter (Amicon 10 kDa nominal 
molecular weight cut-off) and frozen in liquid nitrogen before storage at -80 °C. 
 
Purification of E. coli LolC periplasmic domain 
BL21 (DE3) cells bearing plasmid pET24-EcperLolC were grown in 1L of 2YT medium 
supplemented with 50 µg/mL of kanamycin at 30°C. When the culture had achieved OD600 of 0.8 the 
temperature was reduced to 18 °C and protein expression induced with 0.1 mM IPTG. After 16 h 
further growth, cells were harvested by centrifugation at 4000 g and the pellet resuspended in 50 mL 
of 50 mM HEPES pH 7.5, 300 mM NaCl supplemented with protease inhibitor cocktail (Roche), 
lysozyme and DNAse. Bacteria were lysed by cell disruption (Constant Systems) at 30200 psi before 
removal of bacteria debris by ultracentrifugation (40 mins, 115000 g at 5 °C). The supernatant was 
incubated with Ni-NTA agarose resin (Qiagen) for 1h, washed with 20 mL of 20 mM HEPES pH 7.5, 
300 mM NaCl, 20 mM imidazole and bound protein eluted with 10 mL of the same buffer 
supplemented with 250 mM imidazole. Eluted protein was exchanged into 20 mM HEPES pH 7.5, 
150 mM NaCl using a 10 kDa cut-off centricon device (Amicon) and concentrated to 30 mg/mL, 
before flash freezing and storage at -80°C. 
 
Crystallisation of full-length A. actinomycetemcomitans MacB, E. coli MacB periplasmic and 
cytoplasmic domains and E. coli LolC periplasmic domain  
All crystallisation trials were conducted using the sitting drop vapour diffusion method in 2-drop 
MRC plates. Crystallisation drops were 1 µL in volume, composed of either 333 nL protein solution 
and 666 nL crystallisation reagent, or else 333 nL reagent and 666 nL protein, and were equilibrated 
over an 80 µL volume of the reagent alone. For A. actinomycetemcomitans MacB, protein aliquots (8 
mg/mL) were thawed on ice and 5 mM MgATP or MgATPγS added immediately prior to 
crystallisation. Diffracting crystals were obtained in 100 mM Na-citrate pH 5.5, 21 % (v/v) PEG400 
after 5 days and were harvested a few days later. Crystals of the selenomethionine derivative were 
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obtained in the same conditions. For cryoprotection, single crystals were transferred into a solution 
composed of 75 % (v/v) of the crystallisation reagent from the well reservoir and supplemented with 
25 % (v/v) ethylene glycol and flash frozen in litholoops. Crystals of the MacB cytoplasmic domain 
were obtained using 2.8 M sodium formate, 100 mM sodium acetate pH 4.6. Crystals of the MacB 
periplasmic domain were first obtained as dense, non-diffracting needle clusters in 200 mM 
ammonium acetate, 30 % (v/v) glycerol ethoxylate, 100 mM MES pH 6.5. Subsequent streak seeding 
into a simple optimisation screen yielded thin near 2-dimensional plates in 35 % (v/v) glycerol 
ethoxylate, 100 mM sodium citrate pH 5.6. Further matrix-seeding into several different broad screens 
using these partially-optimised crushed-crystals yielded numerous conditions under which crystals 
grew. Data were collected from crystals grown from seeds in 30 % (v/v) pentaerythritol ethoxylate 
(15/4 EO/OH), 6 % (w/v) polyvinylpyrrolidone, 100 mM HEPES pH 7.5. For cryoprotection, single 
crystals were transferred into a solution composed of 75 % (v/v) of the crystallisation reagent from the 
well reservoir and 25 % (v/v) ethylene glycol before being flash frozen in litholoops. Crystallisation of 
the periplasmic domain of E. coli LolC was carried out by mixing 0.5 µL of protein at 10 mg/mL and 
0.5 µL of reservoir solution composed of 0.2 M ammonium sulfate, 0.1 M sodium acetate at pH 4.6, 
30% (w/v) of PEG 2000 MME. Crystals were grown at 15 °C by the sitting drop vapour diffusion 
method over a reservoir of 80 µL in MRC plates. The cryoprotection solution was composed of the 
reservoir solution supplemented with 25% (v/v) of glycerol before being flash frozen in nylon loops. 
 
Structure determination – E. coli MacB periplasmic and cytoplasmic domains 
X-ray data was collected at Diamond Light Source (UK) and structure solution used programmes from 
the CCP4 suite (17). Data were integrated with Imosflm (18), scaled with Aimless (19), and phased by 
molecular replacement using Phaser (20). The E. coli periplasmic domain was phased using a search 
model comprising the separated subdomains of the A. actinomycetemcomitans periplasmic domain 
(21) (PDB code 3FTJ). For the cytoplasmic domain, molecular replacement used the nucleotide 
binding domain (NBD) from MJ0796 (22) (PDB code 1L2T) as a search probe. To minimise phase 
bias, new phases were calculated using density modification implemented in Parrot (23) without 
recombination with the starting phases. Structural models were built with Buccaneer (24) using the 
density modified map as a starting point followed by cycles of model building and refinement using 
Coot (25) and Refmac (26). Non-crystallographic symmetry (NCS) restraints were used throughout 
refinement where possible. Validation was assisted with tools from Coot (25), Procheck (27), 
Rampage (28), and Molprobity (29). For the MacB cytoplasmic domain, two crystal forms were 
obtained – the first in space group C2221 and another in space group P6122. Statistics for 
crystallographic datasets and refined models pertaining to the MacB soluble domain structures are 
presented in Table S2. Coordinates and structure factors have been deposited with the protein 
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databank, accession codes 5LJA (cytoplasmic form I), 5LJ9 (cytoplasmic form II) and 5LJ8 
(periplasmic domain). 
 
Structure determination – full-length A. actinomycetemcomitans MacB 
Two datasets were collected at Soleil Proxima2 from a single crystal at distinct locations with a 
starting phi rotation 90° apart. A further dataset was collected at Diamond I24 on a second crystal 
isomorphous to the first. Each dataset was integrated and scaled using Imosflm (18) and Aimless (19). 
Radiation damage in each dataset was judged from the batch behaviour of overall statistics such as 
I/σ(I) and Rmerge in the high-resolution bin. Data taken from the first part of each of all three datasets 
was merged and scaled using Aimless (19), and a high resolution cut-off chosen (3.35 Å) taking into 
account the I/σ(I), completeness and CC½ in the outer resolution bin. Similar considerations were 
made for the P6522 dataset. 
 
The location of the cytoplasmic domain within the P21 cell was determined using molecular 
replacement with Phaser (20). A two-copy solution was found in space group P21 using the E. coli 
MacB cytoplasmic domain. After remodelling the A. actinomycetemcomitans sequence on the 
molecular replacement probe, further density was apparent in the asymmetric unit but was not easily 
interpreted. Searching the hexagonal data using the partially refined dimer from the P21 solution 
yielded a clear solution in space group P6522 with a single molecule located beside the two-fold 
crystal symmetry axis. Inspection of the P6522 density map revealed tubular density corresponding to 
the 4 transmembrane helices. The helices were modelled in Coot (25) as geometrically perfect 
polyalanine α-helices and this model transferred back to the P21 form. After a round of refinement 
with Refmac (26) (including jelly-body and NCS restraints), density modification protocols were 
employed with Parrot (23), DM and Resolve (30). The density-modified maps clarified the 
connectivity and directions of the transmembrane helices allowing these to be rebuilt and refined. 
Subsequent molecular replacement searches using the Sabre subdomain from the 
A. actinomycetemcomitans MacB periplasmic domain as a probe (keeping the cytoplasmic domain and 
polyalanine TM helices fixed) revealed the location of the Sabre subdomains. After phase calculation, 
the missing Porter domain was identified by manual inspection of the map. The Porter subdomains 
were manually placed in Coot (25) and refined using rigid body protocol in Refmac (26). Phases 
calculated during subsequent NCS-restrained maximum likelihood refinement of this model were used 
as a starting point for modification in Resolve (30) giving a map for use in model building. Once the 
majority of the protein main chain was built and the connectivity established, the P21-form polyalanine 
model was used to back-solve the P6522 native and selenomethionine datasets by molecular 
replacement. Calculation of an anomalous scattering map using the selenomethionine dataset revealed 
locations of the Selenium positions informing the location of the methionines in the MacB polyalanine 
model. Returning to the P21 dataset, the model was updated with the methionine positions and 
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sequence assignments made where possible. Cycles of model building and maximum likelihood 
refinement were used to iteratively improve the model including additions of side chains. Non-
crystallographic symmetry restraints were applied throughout. Inspection of the NBD revealed density 
for ATPγS, which was modelled as ATP and manually placed with assistance from real space fitting 
procedures in Coot (25). It was not possible to unambiguously identify the location of the oxygen-
replacing sulfur in the ATPγS molecule. Near the end of refinement, validation tools from Coot (25), 
Molprobity (29), and Rampage (28) were used to guide further improvement of the model. In the final 
stages, refinement was switched from Refmac (26) to phenix.refine (31, 32). More than 120 iterative 
rounds of modelling and refinement were used to complete the model of MacB in space group P21. 
The final model of the P21 crystal form includes two MacB monomers, two ATP molecules, two 
magnesium ions and 4 crystallographically ordered waters. Residues 240-245, 312-324, 437-444 were 
not sufficiently well-resolved to model. 
 
The structure of the P6522 MacB crystal form was solved using the 3.35 Å structure of the P21 form as 
a starting model. Since the location of the NBD in the P6522 cell was already known, a single 
monomer of the P21-form MacB structure was superposed using SSM (33) and subjected to rigid body 
refinement against the P6522 data. This served as an initial model for the P6522 form, which was then 
further improved by multiple iterations of model editing with Coot (25) and refinement with 
phenix.refine (31) using the P21 structure as a reference model. As refinement neared convergence, 
reference model restraints were released giving improvements in both Rwork and Rfree. Validation used 
tools from Coot (25), Procheck (27) and Rampage (28). 
 
A final MacB structure was solved at 3.25 Å by refining the P21 form against data collected from a 
single crystal that was co-crystallised with regular ATP. No significant differences were observed, but 
the most complete model was derived from the 3.35 Å data. PDB accession codes for the full-length 
A. actinomycetemcomitans MacB are 5LIL and 5LJ7 for the 3.35 Å and 3.25 Å monoclinic (P21) 
form and 5LJ6 for the hexagonal (P6522) form. 
 
Analysis of protein structures were assisted by various programs; the Dali server (34) was used for 
comparison with known structures, SSM superpose (33) for structural superpositions, ClustalOmega 
(35) for multiple sequence alignments. Positioning of MacB within the lipid bilayer was predicted 
using MEMEMBED (36). Analysis and visualisation of cavities within proteins was performed with 
POREWALKER (9) and HOLLOW (8). The homology model of E. coli MacB in the ATP bound state 
was constructed in I-TASSER (37) based on the full length A. actinomycetemcomitans MacB with 
assistance from our structures of the E. coli NBD (5LJA, 5LJ9 and periplasmic domains (5LJ8). 
Structure images and movies were produced with PyMOL (38). 
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Structure determination – E. coli LolC periplasmic domain 
Data were collected under cryogenic conditions at beamline I03 at Diamond Light Source (UK). The 
structure was refined with the CCP4 package (17). Images were integrated with Imosflm (18) and 
scaled with Aimless (19). The structure was solved by molecular replacement with Phaser (20) using 
the periplasmic domain of A. actinomycetemcomitans MacB (PDB 5LIL) as search model, but 
conserving only the β-sheet of the Porter subdomain. Electron density was improved with Parrot (23) 
before building the model with Buccaneer (24) and several rounds of manual refinement using Coot 
(25) and Refmac (26) with NCS restraints. Data collection and refinement statistics are shown in 
Table S7. 
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